Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Khiron Life Sciences Corp.
  6. Ratings
    KHRN   CA49374L3065

KHIRON LIFE SCIENCES CORP.

(KHRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment
Trading
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth -
EBITDA / Sales
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
-
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
Valuation
P/E ratio
Price Earnings Ratio rating compared the company’s current share price to its per-share earnings for the current fiscal year and the next one
-
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
Price to Book -
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m -
Revision of opinion 12m
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
-
Divergence of analysts' opinions -
Divergence of Target Price
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
Summary
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector Alternative Medicine
1st jan.Capitalisation (M$)Investor Rating
KHIRON LIFE SCIENCES CORP.-18.67%44
CURALEAF HOLDINGS, INC.-1.77%8 448
CANOPY GROWTH CORPORATION-24.55%7 450
BEIJING TONGRENTANG CO., LT..43.14%7 261
DONG-E-E-JIAO CO.,LTD.-21.23%3 039
CRONOS GROUP INC.4.19%2 746
PT INDUSTRI JAMU DAN FARMAS..0.00%1 660
TERRASCEND CORP.-20.55%1 492
AURORA CANNABIS INC.-17.36%1 391
TONG REN TANG TECHNOLOGIES ..18.14%944
BOIRON5.80%909
ORGANIGRAM HOLDINGS INC.92.31%779
JUSHI HOLDINGS INC.-15.46%778
HEXO CORP.6.00%605
CHARLOTTE'S WEB HOLDINGS, I..-4.30%445
PHARMACIELO LTD.-26.44%181
More Results